NCT06573528View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

September 3, 2024

Primary Completion Date

May 9, 2025

Study Completion Date

May 21, 2025

Conditions
MASH
Interventions
DRUG

CS060380

Tablets administered orally

Trial Locations (1)

Unknown

Shanghai Xuhui Central Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Cascade Pharmaceuticals, Inc

OTHER

NCT06573528 - Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects | Biotech Hunter | Biotech Hunter